Острая деструктивная пневмония план обследования
…, . .., . 1 . .. ,
— , , — , , , . , , .
() (, ). , , , , , . , , , .
. . , 40 1000 . , , . 10 1000 /1, 2/. . ( 18- 2–3 /3/), , , , .
( ) 13,1 100 . . (30,4 100 . ), (0,8 100 . ) 10–14 . , .. 15–19 , ( 2,3 100 . ) /4/.
– (), ( ), ( ), .. () ( ). /5, 6, 7/.
, , , . – , (, ), , , , ..
Streptococcus pneumoniae ( 20–60% ); Mycoplasma pneumoniae ( 5–50% ); Chlamydia pneumoniae ( 5–15% ); Chlamydia trachomatis ( 3–10% ); Haemophilus influenzae ( 3–10% ); Enterobacteriaceae (Klebsiella pneumoniae, Escherichia coli .) ( 3–10% ); Staphylococcus aureus ( 3–10% ); Streptococcus pyogenes, Chlamydia psittaci, Coxiella burneti . (). , /7–10/.
, .. . E. oli, K. neumoniae S. aureus . , – . — , , C. trachomatis, / (), . P. carinii, .
6- 6–7 S. pneumoniae, 60% . . H. influenzae b , 7–10% , , , , .
, S. aureus S. pyogenis, , , , , , 2–3%. , , M. pneumoniae C. pneumoniae. , M. pneumoniae . – . C. pneumoniae, , .
, – . – () , – ; 3 1 . . , , . , , , . , , – .
. S. pneumoniae ( 35–40% ), M. pneumoniae (23–44% ), C. pneumoniae (15–30% ). H. influenzae b , Enterobacteriaceae (K. pneumoniae, E. coli .). S. aureus .
/12/. , – P. carinii Candida, M. avium-intracellare . S. pneumoniae, , — ( 1).
1
| Candida | |
| (-, ) | Candida |
| Candida, Aspergillus, Fusarium |
— , . . , , . / / .
/ , , , , .
: , , , , . , , / 60 , 50 , 40 , 38 °C /12/.
:
● () ;
● , ;
● ( ).
, , , , , , 50–70% /8, 12, 13/. , , , , ( ) . , , , , .. , 15–25% .
« » . , :
● ;
● ;
● .
, , . 4–5 . / . .
. >10–12·109/ >10% , <3·109/ >25·109/ .
, – – :
● ( >38 °C);
●;
● ;
● >10–12·109/ / >10%.
, . , , . – . .
, , . , 10–40% /14/. 7–10 . , . .
. , , . -, , , . , , .
/15/ :
● «» , / , / ;
● ;
● «», – , ;
● .
. , , .
, .. . , , . , , -, . -, , , , , , ( , ), , α-.
– , , , IgA. , , , , α1- .
.
– ( ), ( , ..).
, .. .
( ). :
● ;
● ;
● ( );
● ( ).
:
● ;
● ;
● 2–3 ;
● , ;
● ( , ), – , (), ;
● ;
● ( , – , .. , , .., ..) .
() , :
● 80 60 ;
● ;
● , (, );
● – ;
● ;
● , .
( , , , ..). , . , , — ; — , — ( – ).
/5, 7, 8, 12/. .
/ 36–72 , . : 38 °C / , / ; — .
, .. .
– ( + ) I–II ( ), — III–IV (, .) .
, , , , C. trachomatis. (, ) .
, P. carinii. -, -, .
, , – III–IV — , , ; ( , ). , , .
, , , , ( 2).
2
| + II | II III | |
| + III IV | ||
| – | – |
6–7 6–7 3 :
● , ;
● , , ;
● .
— — . , + II . ( , ) , 2–3 , . + , , . .
– . , ( 7–10%) , , H. Influenzae. – , — . pneumoniae, C. pneumoniae, . , III .
— ( ) — . , + , , . III IV , .. ; . .
, – , , IV . ( 3).
3
( 6-7 6-7 )
6–7 2 :
● ;
● , , , .
( ) + . , , + . , , , , + II . III IV . – , M. pneumoniae . Pneumoniae ( 4).
4
( 6-7 18 )
III–IV , . , , , , Enterobacteriaceae (K. pneumoniae, E. coli .), S. aureus S. pneumoniae, – (20 1 ) , . , , , — .. ( 5).
5
| P. carinii Candida | – 20 / 10–12 / B , 150 / 500 1000 / | |
| (K. pneumoniae, E. coli .) (S. aureus, epidermidis .) | III IV + | |
| (-, ) | Candida | – 20 / 10–12 / B , 150 / 500 1000 / |
| Candida, Aspergillus, Fusarium | III IV B , 150 / 500 1000 / |
6 , , .
6
,
| 100–150 . / | /, / | 3–4 | |
| 50–100 /. 12 2–4 6 | /, / | 3–4 | |
| 25–50 /. 12 0,25–0,5 8 | 3 | ||
| + | 20–40 / ( ). 12 0,5 8 1 ( ) 12 | 2–3 | |
| + | 30 / ( ). 12 1 ( ) 8 6 | / | 2–3 |
| II | |||
| 60 /. 12 1–2 8 | /, / | 3 | |
| 50–100 /. 12 0,75–1,5 8 | /, / | 3 | |
| 20–30 /. 12 0,25–0,5 12 | 2 | ||
| III | |||
| 50–100 /. 12 2 8 | /, / | 3 | |
| 50–75 /. 12 1–2 1 | /, / | 1 | |
| 50–100 /. 12 2 8 | /, / | 2–3 | |
| IV | |||
| 100–150 /. 12 1–2 12 | / | 3 | |
| 30–60 /. 12 0,5 6 | /, / | 4 | |
| 30–60 /. 12 1 8 | /, / | 3 | |
| 40 /. 12 1 12 | /, / | 3–4 | |
| 10 / | /, / | 3 | |
| 5 / | /, / | 2 | |
| 15–30 / | /, / | 2 | |
| 5 / | /, / | 2 | |
| 40–50 /. 12 0,25–0,5 6 | 4 | ||
| 15 . /. 12 500 . 12 | 2 | ||
| 5–8 /. 12 0,25–0,5 12 | 2 | ||
| 10 / , 5 / 3–5 . 12 0,5 1 | 1 | ||
| [* 8 *] | |||
| 5 /. 12 0,5–1 8–12 | 2 | ||
| 2,5 /. 12 0,25–0,5 12 | / | 2 | |
, , . 6–10 2–3 . 2–3- . , .
. . :
● ;
● , ;
● ;
● , .
/ , 1–2 . ( 500 800 /), 2–3 , . IgG 800 %. , IgG IgM.
. , . , , .
, , . 20–30 /, , 100–120 / .
, . , . 3–7–10 . , , , .
, , . . 40 °C , 2,5% 0,5–1,0 0,5–1,0 , / /. 10% — 0,2 10 .
, , .
3–5 ( — 7) , , (C. psittaci, Ps. erugenozae, Leptospira, Coxiella burneti), .
, , .
, , , , /16/. , 1–2 .
.
1. / .. .- ., 1999.- . 66–68, 116–120.
2. – 2001 / . . .- ., 2002.- 3.- . 64.
3. : . / .. , .. . – .: , 2000.- 496 .
4. ( 2002 ).- .: , 2003.- 46 .
5. : / .. , .. , .. .- ., 2001.
6. .., .., .. … .- 2001.- . 3.- 4.- . 355–370.
7. : . 2 ./ .. , .. , .. .- .: , 2007.- . 451–168 ( : . ; . 1).
8. / .. .- .: , 2006.- . 187–250.
9. Buckingham S.C. Incidence and etiologies of complicated pneumonic effusion in children 1996–2001// Pediatr. Infect. Dis. J.- 2003.- 22.- 6.- P. 499–504.
10. Juven T., Mertsola J., Waris M. et al. Etiology of community-acquired pneumonia in 254 hospitalized children// Pediatr. Infect. Dis. J.- 2000.- 19.- P. 293–296.
11. Henrickson K.J. …Seminars in Pediatric Infection Diseases, 1998.- V. 9.- 3 (July).- P. 217–233.
12. . WHO/ARI/91/20. Geneva: WHO, 1991.
13. .., .., .., .. // .- 2006.- . 3.- 3.- . 38–46; 4.- . 22–31.
14. Gendrel D. Pneumonies communautaires de l`enfant: etiologie et traitement// Arch. Pediatr.- 2002.- V. 9.- 3.- P. 288–289.
15. Guidelines for manadegment of adult community — acquired lower respiratory tract infections. European Study on Community-acquired Pneumonia (ESOCAP) Committee// Eur. Resp. J.- 1998.- 14.- 986–991.
16. Bush ., Carlsen R.-H., Zach M.S. Growing up with lung disease: the lung in transition to adult life// ERSM- 2002.- P. 189–213.
Источник